An assessment of a population of patients with CML revealed that some are not receiving guideline-based treatment, including TKIs.
Researchers sought to determine whether late mortality rates are affected by exposure to a BCR-ABL TKI prior to BMT in patients with CML who survive at least 2 years posttransplantation.
Key factors that influence choice of TKI for frontline treatment of chronic-phase CML are reviewed, as well as the role for pharmacists in the multidisciplinary oncology care team.
Study sought to determine the effects of dose reductions in TKI therapy prior to complete cessation improves treatment-free remission in patients with CML.
Researchers assessed 13,276 patients with chronic myeloid leukemia to characterize the incidence and types of second malignancies in this patient population.